Kun Run Biotechnology (KURU.OB) Obtains Marketing Approval for Hepatitis-B Treatment from China State Food and Drug Administration
Kun Run Biotechnology Inc., a leading bio-pharmaceutical company in China engaged in manufacturing and sales of peptide-based and small molecule drugs, today announced it has received the manufacturing approval for Entecavir from the China State Food and Drug Administration (SFDA). Entecavir is an oral antiviral drug used in the treatment of Hepatitis-B infection. The drug received U.S. Food and Drug Administration (FDA) approval on March 30, 2005 for the treatment of chronic Hepatitis-B infection in adults. The SFDA gave Hainan Zhonghe Pharmaceutical approval to produce Entecavir tablets under the brand names HeDing and HeEn on May 26, 2010, making it…